Home » Topics » BioWorld Science

BioWorld Science
RSS

Edgewise Therapeutics patents myosin inhibitors

Dec. 9, 2021

New ENPP1 inhibitors discovered at Vir Biotechnology

Dec. 9, 2021

New CDK9/cyclin T1 inhibitors identified at Algen Biotechnologies

Dec. 9, 2021

Shanghai Meiyue Biotech Development describes new coagulation factor XIa inhibitors

Dec. 9, 2021

New model for studying early embryonic development

Dec. 9, 2021

Attenuated T. gondii injection synergizes with PD-L1 checkpoint blockade against mouse tumors

Dec. 9, 2021

Proteogenomics approach identifies neoantigens for T-cell immunotherapy in pediatric brain tumors

Dec. 9, 2021

GreenLight and IAVI partner on mRNA vaccine candidate for SARS-CoV-2 Omicron variant

Dec. 7, 2021

Bsense reports preclinical data on BSEN-627 in rat pain model

Dec. 7, 2021

Alpha Cognition reports preclinical data from ALPHA-1062 intranasal TBI program

Dec. 7, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...